Safety and Efficacy Study of NatrOVA - 1% Creme Rinse and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
Information source: ParaPro Pharmacuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pediculosis Capitis(Head Lice)
Intervention: Spinosad Creme Rinse (Drug); Spinosad Creme Rinse (Drug); Permethrin 1% (Drug)
Phase: Phase 3
Sponsored by: ParaPro Pharmacuticals
Official(s) and/or principal investigator(s):
Bill Miller, MD, Study Director, Affiliation: Concentrics Research
A comparative safety and efficacy study of NatrOVA Creme Rinse - 1% versus NIX Creme Rinse,
under actual use conditions in subjects 6 months of age or greater who are infested with
Pediculosis capitis (human head lice).
Official title: A Phase 3 Comparative Safety and Efficacy Study Between NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects >6 Months of Age or Older With Pediculosis Capitis
Study design: Treatment, Randomized, Double Blind (Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Efficacy of NatrOVA Creme Rinse - 1% relative to NIX Creme rinse in subjects infested with head lice
Secondary outcome: Evaluation of the safety of NatrOVA Creme Rinse - 1% based upon reported adv erse events and observed skin/scalp reactions.
This is a Phase 3 multi-site, randomized, evaluator/investigator-blinded, three-arm, parallel
group study evaluating the safety and efficacy of NatrOVA Creme Rinse - 1% (with nit combing
and without nit combing) versus NIX Creme Rinse in an "actual use" environment.
Minimum age: 6 Months.
Maximum age: N/A.
1. Subjects must have an active head lice infestation present at Day 0.
2. Subjects can be female or male, at least 6 months of age.
3. Subjects must be in good general health based on medical history.
4. Each subject must have an appropriately signed Informed Consent agreement. Subjects
under the age of 12 must also provide written or oral assent.
5. The subject/caregiver must be able to read English or Spanish at a 7th grade level.
6. The parent or guardian within a household must be willing to allow other household
members to be screened for head lice. If other household members are found to have a
head lice infestation, they should also be enrolled in the study.
7. Subjects must agree to not use any other form of lice treatment during the course of
the study and must agree not to use any of the excluded concomitant medications.
8. Subjects must agree not to cut or chemically treat their hair in the period between
the initial treatment and the final visit.
9. Subjects/caregiver must demonstrate a clear understanding of his/her requirements for
study participation and agree to comply with study instructions.
1. Individuals with history of irritation or sensitivity to pediculicides or hair care
2. Individuals with any visible skin/scalp condition at the treatment site which, in the
opinion of the investigative personnel or Sponsor, will interfere with the
3. Individuals who require treatment with topical salicylic acid, topical
corticosteriods, anthralin, vitamin D analogs, retinoids, immunosuppressants, topical
hair growth formulations, and topical dandruff treatments.
4. Infested subjects who have been previously treated with a pediculicide withini the 48
hours prior to the study.
5. Individuals with a condition or illness that, in the opinion of the Investigator, may
compromise the objective of the protocol.
6. Individuals receiving systemic or topical drugs or medications, including systemic
antibiotics, which in the opinion of the investigative personnel or study monitor may
interfere with the study results.
7. Individuals who have participated in a clinical trial within the past 30 days.
8. Individuals (or individuals from households) who, in the opinion of the Investigator,
do not understand the requirements for study participation and/or may be likely to
exhibit poor compliance.
9. Individuals with household members who are infested with lice but are unwilling or
unable to enroll in the study or to use the standard course of lice treatment.
10. Females who are pregnant or nursing. Females of childbearing potential must have a
negative urine pregnancy test prior to treatment at Day 0. If a household has a
pregnant female with an active case of head lice, the entire household is excluded
from participation. If the pregnant household member does not have lice, this
individual must NOT be the caregiver (one who provides treatment to other household
11. Sexually active females not using effective contraception.
12. Individuals who have a history of drug abuse in the past year.
Locations and Contacts
Hill Top Research, Scottsdale, Arizona 85251, United States
Burke Pharmaceutical Research, Hot Springs, Arkansas 71913, United States
Impact Clinical Trials, Beverly Hills, California 90211, United States
DMI Healthcare Group, Largo, Florida 33773, United States
Haber Dermatology & Cosmetic Surgery, South Euclid, Ohio 44118, United States
Hill Top Research, Miamiville, Ohio 45147, United States
Starting date: September 2007
Ending date: May 2008
Last updated: May 16, 2008